retatrutide trial update october 2025 How to Get in 2026 Retatrutide Phase 3 Results 2026:

Analyzing data for the 80 percent of participants not taking a GLP-1 allowed the researchers to factor in diabetes severity

Good candidates People who want a natural, non-pharmaceutical approach

Leveraging the University of California Health Data Warehouse enabled a realworld analysis of 6,871 patients with primary colon cancer and rigorous adjustment strategies to probe whether GLP1 RA exposure relates to fiveyear mortality. At the end of the study, researchers found that participants with colon cancer taking GLP-1 medications had a 15.5% mortality risk within 5 years, compared to 37.1% in participants not taking the drugs

dual GLP-1/GIP agonists, cardiovascular outcome trials, inflammation 1